Chin Kyu Huh, a 10% Holder, disposed of 403,892 Common Shares on a control or direction basis for registered holder ILJIN SNT Co., Ltd. at prices ranging from US$6.127 to US$6.887 between November 21st and 26th, 2019. This represents a $3,495,495 divestment of the company's shares and an account share holdings change of -3.2%.
Aurinia Pharmaceuticals is in the Biotechnology & Medical Research Sub Industry Group under the Healthcare Sector.
Aurinia Pharmaceuticals Inc. is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company's primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN. Voclosporin is an oral drug, administered twice daily. It is structurally similar to cyclosporine A (CsA), but is chemically modified on the amino acid-1 residue. It has completed two Phase III clinical studies in patients with moderate to severe psoriasis. It has completed Phase IIb clinical trial, which is a randomized, controlled, double-blind study comparing the efficacy of voclosporin as a component of multi-targeted therapy against placebo in achieving remission in patients with active LN. Aurinia Pharmaceuticals Inc. (AUP) has a high amount of executive buying compared to its mid-cap peers in the market over the past three months. According to regulatory filings yesterday, one insider has divested a net amount of $3,495,495.
No Comments